CN101961336B - 治疗哺乳动物包括人2型糖尿病的药物组合物 - Google Patents

治疗哺乳动物包括人2型糖尿病的药物组合物 Download PDF

Info

Publication number
CN101961336B
CN101961336B CN2009101403973A CN200910140397A CN101961336B CN 101961336 B CN101961336 B CN 101961336B CN 2009101403973 A CN2009101403973 A CN 2009101403973A CN 200910140397 A CN200910140397 A CN 200910140397A CN 101961336 B CN101961336 B CN 101961336B
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
pioglitazone
rosiglitazone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2009101403973A
Other languages
English (en)
Chinese (zh)
Other versions
CN101961336A (zh
Inventor
袁开红
马淑芹
刘华文
朱亚飞
李雷明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN2009101403973A priority Critical patent/CN101961336B/zh
Priority to PCT/CN2010/074309 priority patent/WO2011009360A1/fr
Publication of CN101961336A publication Critical patent/CN101961336A/zh
Priority to HK11107352.4A priority patent/HK1153143A1/xx
Application granted granted Critical
Publication of CN101961336B publication Critical patent/CN101961336B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009101403973A 2009-07-21 2009-07-21 治疗哺乳动物包括人2型糖尿病的药物组合物 Active CN101961336B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2009101403973A CN101961336B (zh) 2009-07-21 2009-07-21 治疗哺乳动物包括人2型糖尿病的药物组合物
PCT/CN2010/074309 WO2011009360A1 (fr) 2009-07-21 2010-06-23 Composition pharmaceutique pour le traitement du diabète de type 2 chez des mammifères comprenant les êtres humains
HK11107352.4A HK1153143A1 (en) 2009-07-21 2011-07-15 Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101403973A CN101961336B (zh) 2009-07-21 2009-07-21 治疗哺乳动物包括人2型糖尿病的药物组合物

Publications (2)

Publication Number Publication Date
CN101961336A CN101961336A (zh) 2011-02-02
CN101961336B true CN101961336B (zh) 2012-05-30

Family

ID=43498754

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009101403973A Active CN101961336B (zh) 2009-07-21 2009-07-21 治疗哺乳动物包括人2型糖尿病的药物组合物

Country Status (3)

Country Link
CN (1) CN101961336B (fr)
HK (1) HK1153143A1 (fr)
WO (1) WO2011009360A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108144065B (zh) * 2016-12-06 2023-05-16 江苏恒瑞医药股份有限公司 一种dpp-4抑制剂的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101287495A (zh) * 2005-06-10 2008-10-15 诺瓦提斯公司 Dpp-iv抑制剂和格列酮的直接压片的制剂和制备方法
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101287495A (zh) * 2005-06-10 2008-10-15 诺瓦提斯公司 Dpp-iv抑制剂和格列酮的直接压片的制剂和制备方法
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CN101961336A (zh) 2011-02-02
WO2011009360A1 (fr) 2011-01-27
HK1153143A1 (en) 2012-03-23

Similar Documents

Publication Publication Date Title
CN101365432B (zh) 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
US20120059011A1 (en) Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
CN106075451A (zh) 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
CN106924208A (zh) 一种复方达格列净二甲双胍缓释片及其制备方法
JP2013508370A (ja) ジペプチジルペプチダーゼ−４阻害剤とピオグリタゾンとの組み合わせの医薬組成物
CN101919851B (zh) 治疗哺乳动物包括人2型糖尿病的药物组合物
CN103893142A (zh) 一种沙格列汀分散片及其制备方法
JP2022544167A (ja) ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用
CN101961336B (zh) 治疗哺乳动物包括人2型糖尿病的药物组合物
CN101904840B (zh) 治疗哺乳动物包括人2型糖尿病的药物组合物
CN103877043A (zh) 一种磷酸西他列汀分散片及其制备方法
EP2402342B1 (fr) Composition pharmaceutique servant a traiter le diabete de type 2
US8476272B2 (en) Pharmaceutical composition for treatment of type 2 diabetes
CN109288836B (zh) 一种复方硫酸双肼屈嗪制剂及其制备方法和应用
CN106074553A (zh) 含有西格列汀和二甲双胍的药物组合物
TWI494313B (zh) 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
TWI462925B (zh) 治療２型糖尿病的藥物組合物
TWI484955B (zh) 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
TWI826841B (zh) 包含格米列汀與達格列淨的口服組合製劑及其製備方法
TW201219384A (en) Pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1153143

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1153143

Country of ref document: HK